Liposomal Nanosystems in Rheumatoid Arthritis

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Ferreira Silva, M (Author) Other; Faria Silva, C (Author) Other; Baptista, PV (Author) Other; Eduarda Fernandes (Author) FFUP; Fernandes, AR (Author) Other; Corvo, ML (Author) Other

Journal

Title: Pharmaceutics

Vol. 13

Final page: 454

ISSN: 1999-4923

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 2 Citations

Other information

Authenticus ID: P-00T-SNH

DOI: 10.3390/pharmaceutics13040454

Abstract (EN): Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints and results in reduced patient quality of life due to its chronic nature and several comorbidities. RA is also associated with a high socioeconomic burden. Currently, several available therapies minimize symptoms and prevent disease progression. However, more effective treatments are needed due to current therapies' severe side-effects, especially under long-term use. Drug delivery systems have demonstrated their clinical importance-with several nanocarriers present in the market-due to their capacity to improve therapeutic drug index, for instance, by enabling passive or active targeting. The first to achieve market authorization were liposomes that still represent a considerable part of approved delivery systems. In this manuscript, we review the role of liposomes in RA treatment, address preclinical studies and clinical trials, and discuss factors that could hamper a successful clinical translation. We also suggest some alterations that could potentially improve their progression to the market.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 25